BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
21
- −15 vs. Q1 2026
- Total value $1.22M
Superinvestors holding BCAB
0
- None of the superinvestors held BCAB at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by BCAB insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jan 19, 2024 | Mar 28, 2023 | MCBRINN SYLVIADirector | PPurchaseCommon Stock | +4K | $2.35 | +$9.4K | 19.13K | +26.4% | SEC |
| Dec 26, 2023 | Dec 26, 2023 | MCBRINN SYLVIADirector | PPurchaseCommon Stock | +4K | $2.33 | +$9.32K | 15.13K | +36.0% | SEC |
| Dec 20, 2023 | Dec 20, 2023 | SHORT JAY M PHDChief Executive Officer | PPurchaseCommon Stock | +50K | $2.14 | +$107K | 1.44M | +3.6% | SEC |
| Dec 19, 2023 | Dec 19, 2023 | STEINMAN LAWRENCEDirector | PPurchaseCommon Stock | +20K | $2.05 | +$41K | 38.46K | +108.3% | SEC |
| Dec 19, 2023 | Dec 19, 2023 | Vasquez ChristianSee Remarks | PPurchaseCommon Stock | +7.5K | $2.04 | +$15.29K | 115.66K | +6.9% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in BCAB at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | 108,126 | $447.65K | 0.12% | −5,298,219−98.0% | Reduced |
| MILLENNIUM MANAGEMENT LLC | 70,616 | $292.35K | 0.00% | −2,686,058−97.4% | Reduced |
| Lido Advisors, LLC | 16,656 | $68.96K | 0.00% | +16,656 | New |
| Stonepine Capital Management, LLC | 16,432 | $68.03K | 0.05% | −48,955−74.9% | Reduced |
| ACADIAN ASSET MANAGEMENT LLC | 14,294 | $58K | 0.00% | −1,219,625−98.8% | Reduced |